Core Viewpoint - The company, 佛塑科技, is collaborating with 中石化湖南石油化工有限公司 to establish a project company in 岳阳, Hunan Province, focusing on the development of a polyamide-nylon film project to enhance its market competitiveness and extend its nylon film business upstream in the industry chain [1][2] Group 1 - The project company will have a registered capital of 960 million yuan, with 佛塑科技 contributing 576 million yuan for a 60% equity stake, while 湖南石化 will invest 384 million yuan for a 40% stake [1] - The total planned investment for the project is 3.469 billion yuan, which includes value-added tax and working capital, while the investment excluding these factors is 2.792 billion yuan [1] - The project aims to build production lines for polyamide chips and nylon films, focusing on the production and operation of these products [1] Group 2 - The project will leverage the upstream and downstream industrial chain of "caprolactam—PA6 chips—BOPA film," creating a synergistic effect between 佛塑科技 and 湖南石化 [2] - 佛塑科技 will utilize its technical advantages in BOPA film and management experience, while 湖南石化 will contribute its expertise in PA6 chips and project construction [2] - The project is located in the same industrial park as 湖南石化's caprolactam project, which will enhance the overall synergy, raw material supply, operational efficiency, and cost advantages of the integrated PA6 chips—BOPA film project [2]

集海资源(02489)发布公告，由于邓格庄矿发生事故造成一名工人伤亡，应急局及安监局已责令邓格庄 矿停产整顿和调查。停产后，公司严格按照要求，对烟台牟金的管理工作进行了全面自查自纠。根据应 急局及安监局的指示，烟台市牟平区应急管理局对邓格庄矿进行了深入检查，而烟台牟金亦按要求完成 所有整改。 停产期间，应急管理局与相关当地政府部门对邓格庄矿进行联合审查，确认邓格庄矿符合安全生产条 件。于2025年9月26日，烟台牟金收到由应急管理局发出的《(安全生产行政执法文书)整改覆查意见 书》((鲁烟牟)应急复查(2025)138号)，允许邓格庄矿复工复产。因此，烟台牟金已立即恢复邓格庄矿的 生产。 公司董事会认为，鉴于邓格庄矿停产时间较短，停产将不会对集团财务业绩产生重大影响。 ...

Core Viewpoint - China Jinshi (01380) announced the grant of stock options to several qualified individuals, allowing the purchase of a total of 4.89 million shares, which represents approximately 1.32% of the total issued shares as of the announcement date [1] Summary by Relevant Sections - Stock Option Grant - The company has granted stock options under its stock option plan adopted on June 29, 2020, prior to the new regulations effective January 1, 2023 [1] - The stock options allow for the subscription of 4.89 million ordinary shares with a par value of HKD 0.01 each [1] - Share Capital Impact - The granted stock options correspond to about 1.32% of the total issued share capital of the company as of the announcement date [1]

新华通讯频媒(00309)发布截至2025年6月30日止3个月业绩，收益8953.4万港元，公司拥有人应占亏损 127.4万港元，每股基本亏损0.00066港元。 ...

新兴印刷(01975)公布，将于2025年12月22日派发末期股息每股2.5港仙。 ...

新兴印刷(01975)公布，将于2025年12月22日派发特别股息每股1港仙。 ...

新华通讯频媒(00309)公布，由于公司已解决导致核数师就上市规则第13.50A条发出不发表意见的相关 问题，公司已向联交所申请自2025年9月29日上午九时正起恢复公司股份于联交所的买卖。 ...

董事会认为，本公司与无忧健康签署战略合作备忘录，可将本集团的大健康业务深化，加强本集团的竞 争力，提升本集团的财务表现及盈利能力，符合本公司及其股东的整体利益。 于订立战略合作备忘录后，双方将就社区大健康服务平台及其服务内容方面开展相关的市场分析、行业 研究，并会尽快开始人员沟通及实地考察工作，包括但不限于健康平台的选址、服务内容、管理人员安 排、选品或开发新产品的规划等。 中国健康科技集团(01069)发布公告，于2025年9月26日，本公司与无忧健康(控股)集团有限公司(无忧健 康)订立不具法律效力及约束力的战略合作备忘录(战略合作备忘录)，根据战略合作备忘录，双方同意开 展有关社区大健康服务平台建设及大健康产品开发与销售方面的合作(合作业务)。 根据战略合作备忘录，本公司拟通过无忧健康的的市场优势及大健康产品，共同在中国健康产业探讨合 作机遇，促进本集团大健康产业发展，开发和销售业务板块，拓展未来业务多样性和提升未来的利润增 长点。同时，本集团亦可以通过自有的大健康品牌与无忧健康共同开发大健康产品，利用市场管道促进 合作业务的推广及销售。 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for five companies, including Hunan Mai Ji Bio-Tech Co., Ltd. (Mai Ji Bio), which is seeking to list on the Hong Kong Stock Exchange [1][2] - Mai Ji Bio is a biopharmaceutical company focused on discovering, developing, and commercializing innovative biological agents to address unmet medical needs in allergic and autoimmune diseases [2][3] - The company has developed a strong pipeline of eight innovative candidate products since its establishment in 2016, including core products MG-K10, MG-014, and MG-013 [2][3] Group 2 - The CSRC has requested Mai Ji Bio to clarify the pricing basis for past capital increases and equity transfers, and to confirm compliance with capital contribution obligations [1][2] - Mai Ji Bio's core product, MG-K10, is a long-acting anti-IL-4Rα antibody currently in clinical trials for atopic dermatitis and asthma, showing promising safety and efficacy data [3] - The company must address potential impacts from a patent ownership dispute with Sanofi on its business operations and the upcoming IPO [2]

Group 1 - The company Miniso (09896) plans to spin off its subsidiary TOP TOY through an independent listing on the Hong Kong Stock Exchange [1] - The company has submitted a spin-off proposal to the Hong Kong Stock Exchange, which has confirmed that the proposed spin-off can proceed [1] - TOP TOY submitted its listing application form (A1 form) to the Hong Kong Stock Exchange on September 26, 2025, through its joint sponsors [1] Group 2 - The proposed spin-off will be conducted through a global offering and distribution, and TOP TOY will remain a subsidiary of the company after the spin-off is completed [1] - TOP TOY was registered in the Cayman Islands on April 24, 2025, and is a trendy toy collection company primarily engaged in the design, development, procurement, and sales of trendy toys [1]